Clinical Trial Detail

NCT ID NCT01362374
Title Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Genentech
Indications

Advanced Solid Tumor

Therapies

Enzalutamide

Paclitaxel

Docetaxel

Ipatasertib

Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.